February 18, 2021
Six Campbell faculty members were selected to serve in various roles with professional organizations – North Carolina Association of Pharmacists (NCAP) and the American College of Clinical Pharmacy (ACCP).
Dr. Byron May, chairman and professor of the Department of Pharmacy Practice, shared, “We would like to congratulate all the candidates on their newly appointed roles in service to these organizations and to the profession. In addition to these roles,
Dr. Beth Mills, clinical assistant professor of Ambulatory Care, will serve as the 2021 NCAP President.”
Dr. Paige Brown, assistant dean of Interprofessional Education and clinical associate professor of Pharmacy Practice was elected to serve as secretary for the NCAP Board of Directors. Brown graduated from Campbell’s Doctor of Pharmacy program in 2006 and has served in various capacities such as clinical pharmacist, pharmacy education specialist, clinical assistant professor, and vice chair of Experi
Bennett Doughty grew up in Winthrop, Maine, and earned his Doctor of Pharmacy degree with honors from the University of Connecticut School of Pharmacy in 2016. Following graduation, Doughty completed two years of residency training at the VA Connecticut Healthcare System in West Haven, Conn., specializing in psychiatric pharmacy.
Doughty joined the Binghamton School of Pharmacy and Pharmaceutical Sciences in 2018 as a clinical assistant professor in the Department of Pharmacy Practice. He also serves as a clinical psychiatric pharmacy specialist at the Guthrie Robert Packer Hospital in Sayre, Pa., where he works in crisis, inpatient and ambulatory care settings. Doughty is the program director of the Binghamton University Opioid Overdose Prevention Program (BU OOPP), a state-sponsored program that supports the training and distribution of the opioid overdose reversal agent, Narcan, to the University community. He is actively working with healthcare faculty members across Binghamton
Managing Editor
The first vaccine to prevent COVID-19 has been cleared for use in the United States. The Food and Drug Administration on Saturday granted emergency use authorization to Pfizer and BioNTech’s COVID-19 vaccine for use in individuals 16 years old and older. The first shipments began leaving facilities on Sunday.
The FDA’s decision was based on data from its Phase 3 clinical study, whose results were published last week in the New England Journal of Medicine and which saw a 95% vaccine efficacy rate. The two companies continue to gather additional data and prepare a biologics license application for full approval from the FDA in 2021.
Share this article
Share this article
WASHINGTON, Dec. 11, 2020 /PRNewswire/ The leaders of 18 pharmacy organizations today issued the following statement following the Food and Drug Administration s approval of the first Emergency use Authorization for the COVID-19 vaccine. We heartily welcome the decision by the US Food and Drug Administration (FDA) to authorize the emergency use of the first COVID-19 vaccine, following the recommendation of the Vaccines and Related Biological Products Advisory Committee (VRBPAC). This is a historic moment in the nation s effort to end the pandemic. The pharmacy profession is ready to do its part as qualified, active participants in administering these vaccines in accordance with guidance issued by the FDA, CDC, HHS and state and local health departments, as well as increasing access for the American public to these important disease prevention tools.